May 14, 2018 / 12:12 PM / 6 months ago

BRIEF-Soleno Therapeutics Announces Initiation Of Phase III Clinical Trial Of DCCR In Prader-Willi Syndrome

May 14 (Reuters) - Soleno Therapeutics Inc:

* SOLENO THERAPEUTICS ANNOUNCES INITIATION OF PHASE III CLINICAL TRIAL OF DCCR IN PRADER-WILLI SYNDROME

* SOLENO THERAPEUTICS ANNOUNCES INITIATION OF PHASE III CLINICAL TRIAL OF DCCR IN PRADER-WILLI SYNDROME

* SOLENO THERAPEUTICS INC - TRIAL IS ANTICIPATED TO TAKE APPROXIMATELY 9-12 MONTHS TO COMPLETE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below